JANX Stock Analysis: Janux Therapeutics | NASDAQ

Biotechnology | NASDAQ, USA | Market Cap: 894m USD | 12M Return: -32.6% | Charts, Fundamentals & Technical Analysis

Cancer Immunotherapy, Prostate Cancer, Solid Tumors, Autoimmune Diseases
Total Rating 17
Safety 37
Buy Signal -0.02
Biotechnology
Industry Rotation: +30.9
Market Cap: 894M
Avg Turnover: 15.7M
Risk 3d forecast
Volatility79.4%
VaR 5th Pctl11.8%
VaR vs Median-8.17%
Reward TTM
Sharpe Ratio-0.10
Rel. Str. IBD16.9
Rel. Str. Peer Group6.3
Character TTM
Beta1.057
Beta Downside1.043
Hurst Exponent0.446
Drawdowns 3y
Max DD81.78%
CAGR/Max DD0.13
CAGR/Mean DD0.23
EPS (Earnings per Share) EPS (Earnings per Share) of JANX over the last years for every Quarter: "2021-06": -0.62, "2021-09": -0.26, "2021-12": -0.33, "2022-03": -0.32, "2022-06": -0.41, "2022-09": -0.4, "2022-12": -0.39, "2023-03": -0.42, "2023-06": -0.42, "2023-09": -0.25, "2023-12": -0.25, "2024-03": -0.3, "2024-06": -0.11, "2024-09": -0.51, "2024-12": -0.36, "2025-03": -0.38, "2025-06": -0.55, "2025-09": -0.39, "2025-12": -0.51, "2026-03": -0.39,
Last SUE: 0.95
Qual. Beats: 3
Revenue Revenue of JANX over the last years for every Quarter: 2021-06: 0.482, 2021-09: 1.159, 2021-12: 1.616, 2022-03: 1.589, 2022-06: 2.365, 2022-09: 1.813, 2022-12: 2.845, 2023-03: 2.048, 2023-06: 1.057, 2023-09: 2.517, 2023-12: 2.461, 2024-03: 1.252, 2024-06: 8.897, 2024-09: 0.439, 2024-12: -8.512, 2025-03: 0, 2025-06: 0, 2025-09: 10, 2025-12: 7.88, 2026-03: 3.733,
Rev. CAGR: 11.23%
Rev. Trend: 74.8%
Last SUE: -0.25
Qual. Beats: 0

Warnings

High Debt While Negative Cash Flow
Beneish M-Score Likely Earnings Manipulation
Below Sma 200d

Tailwinds

No distinct edge detected

Seasonality 5 years of data

Jan -2.8% 0
Feb -10.9% 22
Mar -16.8% 27
Apr +24.4% 47
May -12.6% 42
Jun +0.3% 9
Jul +5.9% 23
Aug -4.3% 20
Sep +5.9% 0
Oct +17.3% 28
Nov +1.1% 0
Dec +9.2% 0

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: JANX Janux Therapeutics

Janux Therapeutics is a clinical-stage biopharmaceutical company developing immunotherapy drug candidates for cancer and autoimmune diseases using three proprietary platforms: Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM). Its lead candidates include JANX007, in Phase 1 trials for metastatic castration-resistant prostate cancer, JANX008, in Phase 1 trials targeting multiple solid tumor types, and JANX011, a CD19-targeted candidate aimed at autoimmune diseases. The company also has strategic research and development collaborations with Merck Sharp & Dohme and Bristol Myers Squibb to advance its pipeline.

Founded in 2017 and headquartered in San Diego, California, Janux is a small-cap U.S. biotechnology firm listed on NASDAQ under the ticker JANX. As a clinical-stage company without approved commercial products, its business model relies on advancing candidates through early-stage trials and partnering with larger pharmaceutical companies to fund late-stage development, a common structure in the oncology biotech sector where capital-intensive research is offset by licensing deals and milestone payments from established drugmakers.

Headlines to Watch Out For
  • JANX007 PSMA prostate cancer Phase 1 data catalyst
  • Merck and Bristol Myers Squibb partnership milestones advance pipeline
  • Cash runway extends through key clinical readouts
Piotroski VR-10 (Strict) 1.0
Net Income: -114.5m TTM > 0 and > 6% of Revenue
FCF/TA: -0.08 > 0.02 and ΔFCF/TA -3.21 > 1.0
NWC/Revenue: 4.36k% < 20% (prev 122k%; Δ -118k% < -1%)
CFO/TA -0.08 > 3% & CFO -77.5m > Net Income -114.5m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 17.01 > 1.5 & < 3
Outstanding Shares: last quarter (62.7m) vs 12m ago 1.41% < -2%
Gross Margin: 51.64% > 18% (prev -5.82k%; Δ 5.87k% > 0.5%)
Asset Turnover: 2.08% > 50% (prev 0.08%; Δ 2.00% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM)
Altman Z'' 10.00
A: 0.92 (Total Current Assets 1.00b - Total Current Liabilities 58.9m) / Total Assets 1.03b
B: -0.37 (Retained Earnings -375.7m / Total Assets 1.03b)
C: -0.11 (EBIT TTM -114.5m / Avg Total Assets 1.04b)
D: 10.86 (Book Value of Equity 941.5m / Total Liabilities 86.7m)
Altman-Z'' = 15.49 = AAA
Beneish M 1.00
DSRI: 0.29 (Receivables 42.5m/5.58m, Revenue 21.6m/824k)
GMI: 1.00 (fallback, negative margins)
AQI: 1.35 (AQ_t 0.00 / AQ_t-1 0.00)
SGI: 26.23 (Revenue 21.6m / 824k)
TATA: -0.04 (NI -114.5m - CFO -77.5m) / TA 1.03b)
Beneish M = 14.68 (Cap -4..+1) = D
What is the price of JANX shares?

As of July 08, 2026, the stock is trading at USD 16.15 with a total of 1,290,072 shares traded. Over the past week, the price has changed by +5.38%, over one month by +19.54%, over three months by +8.17% and over the past year by -32.60%.

Current recommended Stop Loss: 15.30 (which is 5.3% or 1.3 ATR below the current price).

Is JANX a buy, sell or hold?

Janux Therapeutics has received a consensus analysts rating of 4.77. Therefore, it is recommended to buy JANX.

  • StrongBuy: 11
  • Buy: 1
  • Hold: 1
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the JANX price?
Analysts Target Price 37.2 130.3%
Janux Therapeutics (JANX) - Fundamental Data Overview as of 03 July 2026
Market Cap USD = 894.0m (894.0m USD * 1.0 USD.USD)
P/S = 65.1009
P/B = 0.9489
Revenue TTM = 21.6m USD
EBIT TTM = -114.5m USD
EBITDA TTM = -112.4m USD
Long Term Debt = 19.1m USD (estimated: total debt 21.6m - short term 2.47m)
Short Term Debt = 2.47m USD (from shortTermDebt, last quarter)
Debt = 21.6m USD (from shortLongTermDebtTotal, last quarter) (leases 21.6m already included)
Net Debt = -934.8m USD (calculated: Debt 21.6m - CCE 956.4m)
Enterprise Value = 894.0m USD (floored to Market Cap, CCE > MCap+Debt)
 Interest Coverage Ratio = unknown (Ebit TTM -114.5m / Interest Expense TTM 0.0)
 EV/FCF = -11.39x (Enterprise Value 894.0m / FCF TTM -78.5m)
FCF Yield = -8.78% (FCF TTM -78.5m / Enterprise Value 894.0m)
 FCF Margin = -363.2% (FCF TTM -78.5m / Revenue TTM 21.6m)
 Net Margin = -529.7% (Net Income TTM -114.5m / Revenue TTM 21.6m)
 Gross Margin = 51.64% ((Revenue TTM 21.6m - Cost of Revenue TTM 10.5m) / Revenue TTM)
Gross Margin QoQ = 87.44% (prev -13.45%)
Tobins Q-Ratio = 0.87 (Enterprise Value 894.0m / Total Assets 1.03b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 21.6m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -90.4m (EBIT -114.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 17.01 (Total Current Assets 1.00b / Total Current Liabilities 58.9m)
Debt / Equity = 0.02 (Debt 21.6m / totalStockholderEquity, last quarter 941.5m)
 Debt / EBITDA = 8.31 (negative EBITDA) (Net Debt -934.8m / EBITDA -112.4m)
 Debt / FCF = 11.91 (negative FCF - burning cash) (Net Debt -934.8m / FCF TTM -78.5m)
 Total Stockholder Equity = 966.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -11.01% (Net Income -114.5m / Total Assets 1.03b)
RoE = -11.85% (Net Income TTM -114.5m / Total Stockholder Equity 966.4m)
RoCE = -11.62% (EBIT -114.5m / Capital Employed (Equity 966.4m + L.T.Debt 19.1m))
 RoIC = -9.32% (negative operating profit) (NOPAT -90.4m / Invested Capital 970.7m)
 WACC = 9.47% (E(894.0m)/V(915.6m) * Re(9.70%) + D(21.6m)/V(915.6m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.70% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.56 | Cagr: 13.98%
 [DCF] Fair Price = unknown (Cash Flow -78.5m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.95 | # QB: 3
Revenue Correlation: 74.80 | Revenue CAGR: 11.23% | SUE: -0.25 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.29 | Chg30d=+8.74% | Revisions=+0% | Analysts=14
EPS next Quarter (2026-09-30): EPS=-0.52 | Chg30d=-0.17% | Revisions=+25% | Analysts=14
EPS current Year (2026-12-31): EPS=-1.76 | Chg30d=+1.40% | Revisions=+75% | GrowthEPS=+3.6% | GrowthRev=+215.9%
EPS next Year (2027-12-31): EPS=-2.70 | Chg30d=+2.72% | Revisions=+79% | GrowthEPS=-52.9% | GrowthRev=-78.0%
[Analyst] Revisions Ratio: +81% (up=22, down=1)